Clinical trial registry record

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 27, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06130787
Last registry update
September 27, 2024
Status
Recruiting
Phase
Phase not reported
Sponsor
University Hospital, Clermont-Ferrand
Enrollment
321
Countries
France
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
NA · SINGLE GROUP · OTHER · NONE
Evidence population
Human clinical study registration
Participants
321
Population
ALL · 18 Years
Duration
2023-11-17 to 2028-11-17
Intervention
Blood and bone marrow sample
Comparator
Not reported
Outcomes measured
Biological age determination — Day 0;Month 3;Month 12; Individual fragility assessment — Day 0;Month 6;Month 12;Month 24;Month 36; Tolerance of tyrosine kinase inhibitors — Day 0;Month 3;Month 6;Month 12;Month 24;Month 36; Distribution of individual clinical fragility levels assessed by Geriatric Core Data set at the time of diagnosis. — Da…; Distribution of individual clinical fragility levels assessed by Rockwood clinical frailty score at the time of diagnos…; Evaluation of therapeutic response through quantification of the BCR::ABL transcript — Month 3;Month 6;Month 12;Month 1…; Assessment of therapeutic response by quantification of residual disease — Month 3;Month 6;Month 12;Month 15;Month 18;M…; Assessment of patients' quality of life — Day 0;Month 6;Month 12;Month 24;Month 36
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Biological age biomarkers · 80%Title contains controlled term: biological age. Title supplies longevity context: frailty, frail. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

biological age biomarkers
Open primary sourceExport JSON